JP2016516076A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516076A5 JP2016516076A5 JP2016503654A JP2016503654A JP2016516076A5 JP 2016516076 A5 JP2016516076 A5 JP 2016516076A5 JP 2016503654 A JP2016503654 A JP 2016503654A JP 2016503654 A JP2016503654 A JP 2016503654A JP 2016516076 A5 JP2016516076 A5 JP 2016516076A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- insulin
- chain
- long
- cooh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 59
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 239000004026 insulin derivative Substances 0.000 claims 27
- 108010092217 Long-Acting Insulin Proteins 0.000 claims 19
- 102000016261 Long-Acting Insulin Human genes 0.000 claims 19
- 229940100066 Long-acting insulin Drugs 0.000 claims 19
- 102000004877 Insulin Human genes 0.000 claims 16
- 108090001061 Insulin Proteins 0.000 claims 16
- 229940125396 insulin Drugs 0.000 claims 16
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 208000013016 Hypoglycemia Diseases 0.000 claims 6
- 206010012601 diabetes mellitus Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 230000002218 hypoglycaemic effect Effects 0.000 claims 5
- 125000002843 carboxylic acid group Chemical group 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 claims 2
- 230000002641 glycemic effect Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 1
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical group CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000003763 carbonization Methods 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims 1
- 108010050259 insulin degludec Proteins 0.000 claims 1
- 229960004225 insulin degludec Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 230000000422 nocturnal effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13160194 | 2013-03-20 | ||
| EP13160194.0 | 2013-03-20 | ||
| US201361804363P | 2013-03-22 | 2013-03-22 | |
| US61/804,363 | 2013-03-22 | ||
| PCT/EP2014/055533 WO2014147141A1 (en) | 2013-03-20 | 2014-03-19 | Insulin dosing regimen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516076A JP2016516076A (ja) | 2016-06-02 |
| JP2016516076A5 true JP2016516076A5 (https=) | 2017-04-27 |
| JP6755175B2 JP6755175B2 (ja) | 2020-09-16 |
Family
ID=47900938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503654A Active JP6755175B2 (ja) | 2013-03-20 | 2014-03-19 | インスリン投薬レジメン |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US20160296602A1 (https=) |
| EP (1) | EP2976096B1 (https=) |
| JP (1) | JP6755175B2 (https=) |
| CN (1) | CN105188736A (https=) |
| WO (1) | WO2014147141A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4808785B2 (ja) | 2005-12-28 | 2011-11-02 | ノボ・ノルデイスク・エー/エス | インスリン組成物および組成物の製造方法 |
| AU2009309623B9 (en) | 2008-10-30 | 2014-10-02 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| DK2632478T3 (da) | 2010-10-27 | 2019-10-07 | Novo Nordisk As | Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller |
| JP2016519127A (ja) | 2013-04-30 | 2016-06-30 | ノヴォ ノルディスク アー/エス | 新規投与レジメン |
| WO2018096164A1 (en) * | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
| MA46890A (fr) * | 2016-11-28 | 2021-04-28 | Novo Nordisk As | Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme |
| WO2018096162A1 (en) * | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
| EP3577140A1 (en) | 2017-02-01 | 2019-12-11 | Novo Nordisk A/S | Procoagulant antibodies |
| JOP20190273A1 (ar) | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
| AR112015A1 (es) | 2017-06-09 | 2019-09-11 | Novo Nordisk As | Composiciones sólidas para administración oral |
| WO2020002428A1 (en) * | 2018-06-26 | 2020-01-02 | Novo Nordisk A/S | System providing dose recommendations for basal insulin titration |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
| SG11202106167XA (en) | 2018-12-11 | 2021-07-29 | Sanofi Sa | Insulin conjugates |
| US12343383B2 (en) | 2019-07-12 | 2025-07-01 | Novo Nordisk A/S | High concentration insulin formulation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06001283A (es) * | 2003-08-05 | 2006-04-11 | Novo Nordisk As | Derivados de insulina novedosos. |
| SI2107069T1 (sl) * | 2003-08-05 | 2013-04-30 | Novo Nordisk A/S | Novi inzulinski derivati |
| JP4808785B2 (ja) * | 2005-12-28 | 2011-11-02 | ノボ・ノルデイスク・エー/エス | インスリン組成物および組成物の製造方法 |
| CN101454019A (zh) * | 2006-04-12 | 2009-06-10 | 百达尔公司 | 速效和长效胰岛素联合制剂 |
| US9034818B2 (en) * | 2007-06-13 | 2015-05-19 | Novo Nordisk A/S | Pharmaceutical formulations comprising an insulin derivative |
| EP2178910B1 (en) * | 2007-08-15 | 2014-10-08 | Novo Nordisk A/S | Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids |
| AU2009309623B9 (en) * | 2008-10-30 | 2014-10-02 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| US20130143803A1 (en) * | 2010-05-10 | 2013-06-06 | Novo Nordisk A/S | Process for the Preparation of Insulin-Zinc Complexes |
| AU2011202239C1 (en) * | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| CN103167878A (zh) * | 2010-10-27 | 2013-06-19 | 诺沃—诺迪斯克有限公司 | 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病 |
| AU2012213432B2 (en) * | 2011-02-01 | 2016-10-13 | Novo Nordisk A/S | Purification of insulin |
| AU2012223282B2 (en) * | 2011-03-01 | 2017-02-02 | Nutrition 21, Llc | Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders |
| CA2872083A1 (en) * | 2012-05-01 | 2013-11-07 | Novo Nordisk A/S | Pharmaceutical composition |
| JP2016519127A (ja) * | 2013-04-30 | 2016-06-30 | ノヴォ ノルディスク アー/エス | 新規投与レジメン |
-
2014
- 2014-03-19 JP JP2016503654A patent/JP6755175B2/ja active Active
- 2014-03-19 WO PCT/EP2014/055533 patent/WO2014147141A1/en not_active Ceased
- 2014-03-19 EP EP14713072.8A patent/EP2976096B1/en active Active
- 2014-03-19 CN CN201480016936.1A patent/CN105188736A/zh not_active Withdrawn
- 2014-03-19 US US14/777,789 patent/US20160296602A1/en not_active Abandoned
-
2017
- 2017-05-22 US US15/601,506 patent/US20170319664A1/en not_active Abandoned
-
2019
- 2019-01-30 US US16/262,383 patent/US20190160155A1/en not_active Abandoned
-
2021
- 2021-12-16 US US17/553,008 patent/US20220152160A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516076A5 (https=) | ||
| DK1965823T3 (en) | Methods of administering hypoglycemics | |
| RU2011117645A (ru) | Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день | |
| Melson et al. | Future therapies for obesity | |
| RU2419452C2 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ hGLP-1, ЭКСЕНДИНА-4 И ИХ АНАЛОГОВ | |
| JP2007523881A5 (https=) | ||
| US20080213288A1 (en) | Combined Use Of A Modulator Of CD3 And A GLP-1 Compound | |
| JP2014520798A5 (https=) | ||
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| AR071990A1 (es) | Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto | |
| JP2011241213A5 (https=) | ||
| JP2011001381A (ja) | Glp−1医薬組成物 | |
| WO2009020802A2 (en) | Treatment for obesity | |
| JP2014520798A (ja) | ポリエチレングリコールまたはその誘導体でpeg化されたエキセンジン−4類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物 | |
| MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
| JP2013526501A5 (https=) | ||
| Brandt et al. | Are peptide conjugates the golden therapy against obesity? | |
| JP2015517458A5 (https=) | ||
| Edmonds et al. | Oral GLP-1 modulators for the treatment of diabetes | |
| RU2014147674A (ru) | Фармацевтическая композиция | |
| Woo | A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus | |
| JP2014500244A5 (https=) | ||
| JP6049625B2 (ja) | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 | |
| Shibata et al. | Effect of glucagon, glicentin, glucagon-like peptide-1 and-2 on interdigestive gastroduodenal motility in dogs with a vagally denervated gastric pouch | |
| Lee et al. | Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact |